Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
about
Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injuryDifferences in electrophoretic behavior between linear and branched PEG-conjugated proteins.Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors.Pre-existing Antibody: Biotherapeutic Modality-Based Review.Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.Anti-TNF in rheumatoid arthritis: an overview.Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Biologic therapy for refractory scleritis: a new treatment perspective.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.Tumor necrosis factor inhibitors in psoriatic arthritis.Certolizumab pegol for the treatment of psoriasis.Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes.Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.Construction, Purification, and Characterization of a Homodimeric Granulocyte Colony-Stimulating Factor.Blocking collagen fibril formation in injured knees reduces flexion contracture in a rabbit model.Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular InflammationN-Monosubstituted Methoxy-oligo(ethylene glycol) Carbamate Ester Prodrugs of Resveratrol
P2860
Q28066686-756672B8-2744-419F-83DA-D4DA0E435F77Q35498298-18F88110-2D56-4761-AC4B-AF7BED8733F3Q36096265-506EF15C-2801-4982-8848-611829C81AE8Q36653888-BEC6D620-8039-4B90-A010-4DE5DB6B9C43Q37327316-4F9EAF93-1A33-4547-811E-FAA234AB74F6Q38269243-59F394EC-CAC9-4161-B66B-55A9B5617208Q38344282-EE7FB7F9-32FE-4A04-A661-A51697690F38Q38435506-7F7218C5-9E94-4E2E-8E05-627473DEB064Q38540353-78927E0C-17FB-4E96-BD0F-9DE3306BB52FQ38576234-9FEFE4D8-E59F-4EAD-B72A-B91E1DD9AD05Q38630959-25D1659F-A481-4A97-90C3-2E75ED9CFD9AQ38645738-8702CEB0-BE64-405A-BDA4-BCC5495C7CB0Q38673326-7DA64647-27D6-4CD0-8D3D-1FD3EE163A44Q38685543-784FB14A-F783-46BB-8524-ABECBD4B306AQ38976796-3E6DD04F-B58D-4D59-906C-9B10563671BFQ38979811-48517E3A-CD3B-40A7-91A6-62D180CF66E9Q40095024-2002116B-58E8-41FD-92F2-CCD62EAABCB0Q42323191-5D7EEB36-35E8-4EC7-8BA0-B42CEFDE072CQ50882900-48D1F361-C12B-4110-9254-AE0F6AC56AB9Q51640029-512AE484-66E7-4DFB-9D2F-F57A77FE360CQ52362617-9C205518-5948-415F-9FC6-2E3682A18990Q55000881-2D5CF30B-60E9-447A-8C43-A7A9F3F03C69Q57767898-A8A484DA-591C-49BD-AB67-1EB8AC574A00Q57974082-F2E311A6-F564-48D4-9720-DDC3A3110F17
P2860
Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pegylation of biological molec ...... perties of certolizumab pegol.
@en
type
label
Pegylation of biological molec ...... perties of certolizumab pegol.
@en
prefLabel
Pegylation of biological molec ...... perties of certolizumab pegol.
@en
P2860
P1433
P1476
Pegylation of biological molec ...... perties of certolizumab pegol.
@en
P2860
P2888
P304
P356
10.1007/S40259-013-0064-Z
P478
28 Suppl 1
P577
2014-04-01T00:00:00Z